Key terms
About AADI
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AADI news
Mar 18
6:15am ET
Aadi Bioscience (AADI) Receives a Hold from H.C. Wainwright
Mar 17
8:05am ET
Aadi Bioscience presents new subgroup analysis in advanced malignant PEComa
Mar 13
12:45pm ET
TD Cowen Keeps Their Buy Rating on Aadi Bioscience (AADI)
Mar 13
8:02am ET
Aadi Bioscience reports Q4 EPS (60c), consensus (65c)
Mar 01
4:16pm ET
Aadi Bioscience publishes long-term efficacy, safety results from AMPECT study
Feb 12
5:17pm ET
Aadi Bioscience files $150M mixed securities shelf
No recent press releases are available for AADI
AADI Financials
Key terms
Ad Feedback
AADI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AADI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
